KALA Insider Trading

Insider Ownership Percentage: 8.32%
Insider Buying (Last 12 Months): $1,999,999.96
Insider Selling (Last 12 Months): $255,095.17

KALA BIO Insider Trading History Chart

This chart shows the insider buying and selling history at KALA BIO by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$73ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$2M-$1M$0$1M$2MTotal Insider BuyingTotal Insider Selling

KALA BIO Share Price & Price History

Current Price: $6.05
Price Change: Price Decrease of -0.27 (-4.27%)
As of 03/28/2025 05:00 PM ET

This chart shows the closing price history over time for KALA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$6.05Closing price on 03/29/25:

SEC Filings (Institutional Ownership Changes) for KALA BIO (NASDAQ:KALA)

24.61% of KALA BIO stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at KALA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$5.11Mbought$560ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10M-$5M$0$5M$10MTotal InflowsTotal Outflows
KALA BIO logo
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Read More on KALA BIO

Today's Range

Now: $6.05
Low: $5.79
High: $6.47

50 Day Range

MA: $7.70
Low: $6.05
High: $11.02

52 Week Range

Now: $6.05
Low: $4.21
High: $11.20

Volume

36,536 shs

Average Volume

85,255 shs

Market Capitalization

$36.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of KALA BIO?

KALA BIO's top insider investors include:
  1. Bros Advisors Lp Baker (Major Shareholder)
  2. Mark T Iwicki (CEO)
  3. Todd Bazemore (Insider)
  4. Mary Reumuth (CFO)
  5. Eric Trachtenberg (Insider)
  6. Darius Kharabi (Insider)
Learn More about top insider investors at KALA BIO.

Who are the major institutional investors of KALA BIO?

KALA BIO's top institutional shareholders include:
  1. Baker BROS. Advisors LP — 19.74%
  2. SR One Capital Management LP — 9.83%
  3. Silverarc Capital Management LLC — 3.79%
  4. ADAR1 Capital Management LLC — 3.62%
  5. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC — 2.94%
  6. Millennium Management LLC — 2.23%
Learn More about top institutional investors of KALA BIO stock.

Which institutional investors are selling KALA BIO stock?

Within the previous quarter, KALA stock was sold by these institutional investors:
  1. ADAR1 Capital Management LLC
  2. Millennium Management LLC
  3. Two Sigma Investments LP
In the previous year, company insiders that have sold KALA BIO company stock include:
  1. Bros Advisors Lp Baker (Major Shareholder)
  2. Mark T Iwicki (CEO)
  3. Todd Bazemore (Insider)
  4. Mary Reumuth (CFO)
Learn More investors selling KALA BIO stock.

Which institutional investors are buying KALA BIO stock?

Within the previous quarter, KALA stock was bought by institutional investors including:
  1. Baker BROS. Advisors LP
  2. Silverarc Capital Management LLC
  3. SR One Capital Management LP
  4. AIGH Capital Management LLC
  5. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC
  6. Geode Capital Management LLC